DDInter842 DDInter1294
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nitisinone
Nitisinone {u} (Compound) resembles {v} (Compound) Nilutamide
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nitisinone
Nitisinone {u} (Compound) resembles {v} (Compound) Nilutamide
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nitisinone
Nitisinone {u} (Compound) resembles {v} (Compound) Flutamide
Flutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nilutamide
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nitisinone
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nilutamide
Grepafloxacin may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone (Compound) resembles Nilutamide (Compound)
Grepafloxacin may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone (Compound) resembles Nilutamide (Compound)
Grepafloxacin may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide (Compound) resembles Nilutamide (Compound)
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone (Compound) resembles Flutamide (Compound) and Flutamide (Compound) resembles Nilutamide (Compound)
Grepafloxacin may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nilutamide (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Grepafloxacin may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nilutamide (Compound)